Intrauterine intervention for fetal disease has been happening for more than 40 years, particularly fetal transfusion for alloimmune anaemia. The first direct intravascular fetal transfusion was in 1984, but intraperitoneal transfusion had been practiced for some years before that. During the last two decades, fewer new procedures have been proposed, but much work has taken place on assessing which procedures should continue to be performed, and also how, on whom, and when.

**FETAL TRANSFUSION**

The indications for in utero treatment of alloimmune red cell and platelet disease have been settled since the early 1990s. Fetal transfusion techniques improved when the haemorheologic implications were elucidated and needle modifications to improve flow and decrease clot formation were designed. Management plans have continued to improve, however, with routine non-invasive detection of rhesus and kell fetal blood group, from maternal blood samples and improved detection of fetal anaemia with fetal cerebral artery blood velocity measured by Doppler. These developments have led to fewer fetuses being put at risk by unnecessary fetal blood sampling and fewer units of expensively prepared special transfusion blood being wasted.

**FETAL SHUNTING**

Drainage of various abnormal intra-fetal fluid collections has been described including from cerebral ventricles, cystic hygomata, pleural cavity, lung cysts, bladder, renal pelvis, peritoneum and cystic tumours, all into the amniotic fluid. Currently, the only procedures still in regular use are pleuro-amniotic and vesico-amniotic shunting. Both of these procedures have recently been the subject of reviews and advice (available online – see references) by NICE.

Despite all the research and clinical practice to date, the place of vesico-amniotic shunting for lower urinary tract obstruction (posterior urethral valves or urethral atresia) is still in question. No randomised controlled studies have been performed, but one has just commenced. NICE have also recently issued guidance and advice about direct intrauterine fetal cystoscopy. This technique, pioneered by Quintero in the early 1990s, has had very little worldwide use and only one publication from Europe, which is included in the NICE assessment.

**ACARDIAC TWINS**

The in utero treatment of pregnancies complicated by the presence of an acardiac twin of significant size has become clear. The blood supply to the acardiac twin should be interrupted early to avoid the demise, through high output cardiac failure, of the normal co-twin (TRAP sequence). There have been a number of approaches to this. Fetoscopically directed laser ablation and ultrasound guided diathermy with 3mm bipolar diathermy forceps applied directly to the umbilical cord are the most published, but there are reports using interstitial laser and radio frequency devices, inserted just inside the acardiac’s umbilicus to ablate the vessels entering the root of the umbilical cord.
TWIN TO TWIN TRANSFUSION SYNDROME (TTTS)

Twin to twin (Fetofetal transfusion, twin oligo-polyhydramnios) is one area where real in utero progress has been made. The morbidity and mortality of TTTS is very high if left untreated, particularly at early gestation where delivery is not a realistic option. Therapeutic interventions have progressed, through amnioreduction of the polyhydramniotic sac, simple septostomy, non-selective, and finally selective fetoscopic, laser ablation of placental vessels. Pioneered by De Lia in the late 1980s, several observational studies and at least one randomised trial in the US should reach a conclusion. The theory is that exposure of spinal nerve to amniotic fluid causes progressive damage in utero. Simply closing or covering the lesion early in gestation should reduce the damage. To date, animal and human research has shown likely benefits in reducing or resolving the Chiari malformation of the cerebellum and a probable reduction in the number of children requiring ventriculo-peritoneal shunts or at least delaying the first insertion of a shunt. The current NIH-funded MOMs randomised trial in the US should reach a conclusion soon.

SPINA BIFIDA

The first ‘repair’ of spina bifida in utero was presented at the International Fetal Medicine and Surgery Society in 1997. The theory is that exposure of spinal nerve material to amniotic fluid causes progressive damage resulting in a worse outcome the longer the fetus is in utero. Simply closing or covering the lesion early in gestation should reduce the damage. To date, animal and human research has shown likely benefits in reducing or resolving the Chiari malformation of the cerebellum and a probable reduction in the number of children requiring ventriculo-peritoneal shunts or at least delaying the first insertion of a shunt. The current NIH-funded MOMs randomised trial in the US should reach a conclusion soon.

DIAPHRAGMATIC HERNIA

The development of diagnostic and management strategies for congenital diaphragmatic hernia and to a lesser extent, CCAML are mirrors for much of fetal surgery. Pioneered by Mike Harrison at the Fetal Treatment Centre at the University of California, San Fransisco, treatment approaches started with a single stage full diaphragmatic repair via a hysterotomy, progressed through extensive research with fetoscopic surgery to ligate or clip the trachea, to the current fetoscopic placement of an occlusive tracheal balloon. The process of appropriate patient selection (liver herniation into chest, lung to head ratio <1:0), basic science experimentation to show that ‘plugged’ lungs developed into functioning lungs and the microinvasive surgical techniques and equipment to enable balloon placement have all coalesced, resulting in a clear treatment strategy supported by randomised trials. The current approach would not have been possible without concomitant improvements in MRI and ultrasound to allow better fetal imaging. Equally, the development of surgical techniques such as the EXIT procedure have improved the transfer to ex utero life. EXIT procedures are now established for situations where there is expected to be significant airway compromise at delivery, caused by neck masses or tumours.

Cystic adenomatoid malformation of the lung management has developed in parallel to identify the small percentage of patients who may benefit from in utero open surgical removal of the tumour because of incipient or established hydrops.

MISCELLANEOUS

There are a number of other areas of direct fetal surgical therapy still being developed, the development often constrained by the rarity of the condition being treated and the number of centres able and willing to attempt new treatments and research them. Fetal cardiac lesions have been treated with varying success rates, from creating larger ASDs in hypoplastic left heart syndrome through balloon or radio frequency therapy to stenotic or atretic aortic and pulmonary valves and direct fetal pacing for congenital heart block. Sacrococcygeal tumours have been successfully treated by open resection, radio frequency ablation of feeding vessels and shunting to reduce their volume. The mainstay of therapy being to reduce or reverse fetal hydrops.

ONGOING CHALLENGES

The biggest single challenge to most of the approaches above has been the problem of entering the amniotic cavity and leaving it ‘watertight’ at the end. Post-procedure leakage of amniotic fluid, often followed by preivable or very preterm delivery remains the most difficult obstacle to overcome. Preterm labour has been greatly improved by reduction in instrument size or degree of intervention, combined with modern tocolytic (contraction stopping) drugs, but we still have to solve the problem of sealing a hole in an avascular membrane that has no intrinsic self-healing mechanism. The best hopes to date involve biological glues such as the amniopatch procedure.

THE FUTURE

To date the majority of intrauterine fetal surgical therapies have been directed at structural fetal anomalies with the aim being to resolve them prenatally or perhaps to optimise fetal condition long enough to allow growth.
and development in utero to a stage where delivery and definitive postnatal treatment is possible. The great hope for the future is treatment of medical conditions such as cystic fibrosis and Huntingdon’s by gene transplant or haematological and other disorders with stem cell transplantation. The research is well under way and we look forward to a continually developing future in utero fetal surgery and medicine.

KEYPOINTS

• Fetal surgery has progressed to include transfusion and direct surgical interventions.
• Currently, only pleuro-amniotic and vesico-amniotic shunting are undertaken regularly.
• Acardiac twin ablation of blood supply is performed with either laser ablation or ultrasound guided diathermy.
• The effectiveness of spina bifida repair, intrauterine cardiac fetal surgery and tumour surgery are at an early stage of assessment.
• Post-procedure leakage of amniotic fluid leading to preterm delivery remains a significant problem.

REFERENCES

4 http://www.nice.org.uk/guidance/IPG202 (Vesico-amniotic shunting)
5 http://www.pluto.bham.ac.uk (PLUTO Trial)
6 http://www.nice.org.uk/guidance/IPG205 (Fetal cystoscopy)
7 http://www.nice.org.uk/guidance/ipg198/?c=91520c (TTTS Laser)
8 http://www.nice.org.uk/guidance/ipg198/?c=91520c (TTTS Laser)